

# Patented Technology for Enhanced Cannabis Delivery to the Skin



Focused on bringing proven science to the global cannabis space with its topical & transdermal products all powered by its unique, patented skin delivery system Invisicare®.



CSE: OVAT  
OTCQB: OVATF

## COMPANY HIGHLIGHTS

### OUR PRODUCTS:



### OVATION BRANDS:

**INVIBE® MD:** Our CBD Health & Wellness line Invisicare® MD is enhanced with hemp-derived CBD and delivered by patented INVISCARE® skin technology. Products include Relief & Relax, Troubled Skin and Keep Fit Sports Cream.

**INVIBE® MD CANNABIS:** Our CBD-THC, CBN and CBG combination products which are licensed and distributed in Nevada, Oklahoma, Missouri, New Mexico and Mississippi. They are marketed under our licensees' brands.

**ARLO CBD BEAUTY:** Our anti-aging product line, available in the US, helps fight the signs of aging with a rejuvenating day cream, a renewing night cream, a restoring eye cream as well as a super moisturizing hand & body lotion, with more products to come. Products were developed using proven anti-aging ingredients with scientific evidence of their effectiveness at reducing the effects of aging, all enhanced with the power of CBD from hemp and delivered by Invisicare® drug delivery technology.

**US LICENSEES:** 1.) Newly signed licensee is *Stash House Distribution* for the states of Oklahoma, Missouri, New Mexico and Mississippi. Stash House is a national leader in cannabis distribution; distributing the top national brands in the country. Their technology platform, coupled with their deep domain experience in distribution and sales, separates Stash House from the rest of the market.

2.) Ovation's Nevada licensee since 2017, *Lighthouse Strategies, LLC*, has launched seven Ovation formulations under the brand name "BASKiN", with products being awarded multiple awards including the "Best High-Dose CBD Topical" designation in Nevada by Leafly as well as "the world's first recreational cream" (50mg CBD+500mgTHC) & has been consistently one of the #1 selling topical brand (by # of units - Headset.io) in Nevada dispensaries since its launch.

### OUR SCIENCE:

All products developed using Ovation's Invisicare® patent delivery system are developed using pharmaceutical-grade product development processes and backed by 20+ years of science;

Our highly effective formulations are designed to deliver cannabis both topically and transdermally (into the blood stream) and studies prove we provide a greater release and penetration of active ingredients to and through the skin; up to five to ten times greater than brand leaders tested.

### OUR PATENTS:

OVATION's products are protected by comprehensive patent protection in the United States and Canada (pending). Ovation has also trade secrets which protects both our delivery system and our product formulations.

## BUSINESS MODEL:

Ovation will generate online and wholesale revenue from our CBD lines: ARLO CBD Beauty product line & our Invibe® MD medical/ wellness line. Ovation's out-licensing business model generates revenue from multiple revenue streams including on-going royalties based on revenues and sales of Invisicare polymer to its licensees.

## THE POTENTIAL:

The cannabis market potential is global for countries / states where medical marijuana and/or adult-use is legalized; with an estimated growth to \$200 billion by 2028. The CBD (hemp) market is estimated to grow to \$63 billion globally by 2030.

## FUTURE GROWTH:

To continue to grow revenues, Ovation is investing in marketing, business development & new product development:

- Ovation continues to capture a share of the topical CBD market in the US and globally where approved;
- Expand its licensees for Ovation's topical and transdermal products both in the US and globally;
- Develop new product formulations with other cannabinoids such as CBN and CBG.
- Partner with a pharmaceutical company to develop synthetic marijuana products (i.e. Synthetic THC/CBD);

## OVATION SHARES:

Ovation Science Inc.	# ISSUED	RESERVE	FULLY DILUTED
# of SHARES as of 9/22	29,374,836	5,687,800	35,062,636

**CSE: OVAT**  
**OTCQB:OVATF**

## DERMATOLOGY ADVISORY BOARD:

Ovation has a Medical Dermatology Advisory Board for cannabis formulated products with a team of prominent dermatologists including: chaired by Dr. Chuck Lynde (University of Toronto), Dr. Jeffrey Dover (Yale University), Dr. Leon Kircik (Indiana University) & Dr. Richard Thomas (United Kingdom; formerly Qatar and Canada). The objective of the Advisory Board is to reinforce the science behind Ovation's products by providing clinical, scientific, research and strategic advice to the Company as it continues to advance it's topical and transdermal cannabis product development and to maintain and support the Company's advantage in the topical cannabis market globally.

## MANAGEMENT & DIRECTORS:

OVATION has a team with decades of experience in business development and financial markets and over 75 years of combined experience in dermatology, product research & development:

- **Terry Howlett, President & CEO, Director.** Over 35 years of entrepreneurial, business management and public market initialization experience in the pharmaceutical and skincare markets.
- **Doreen McMorran, Chief Operating Officer, Director.** Over 25 years of experience in the medical and pharmaceutical industry, specifically in the areas of strategic planning, sales and marketing of dermatology products.
- **Logan B. Anderson, Chief Financial Officer, Director.** An experienced financial and management expert with over 30 years of public market experience.
- **David Ryan, Director.** Has extensive experience in investment and public markets. For the past 25 years he has been instrumental in bringing multiple Initial Public Offerings to market.
- **Ian Howard, Director.** Over 40 years of extensive experience in marketing, government and health care as well as over 25 years of business experience with Fortune 500 companies internationally.
- **Joan Chypyha, Director.** A pharmaceutical executive with over 25 years in senior management positions including General Manager of a TSX listed company.
- **James Roszell, PhD, Head of Product Development.** A doctoral chemist & developer of Invisicare®, with over 40 yrs experience in product formulation, experimental design, analysis, and method validation.

OVATION is an ancillary supplier to the cannabis industry, supplying its polymer delivery system Invisicare® and licenses its formulations. (It does not sell any components containing marijuana.) Ovation does not sell or distribute any products that are in violation of the United States Controlled Substances Act.

This document contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on current expectations, projections and assumptions about future events. Although Ovation Science Inc. believes that these expectations, projections, and assumptions are reasonable, these forward-looking statements are subject to risks, uncertainties and assumptions about its business operations. As such, the forward-looking events referred to in this document may not occur and actual results may differ materially from those expressly or impliedly anticipated in these forward-looking statements. Investors are advised not to place undue reliance on these forward-looking statements. **NOT FOR DISSEMINATION IN THE USA.**

Copyright 2022 © Ovation Science Inc., All Rights Reserved.

For more information contact: [info@ovationscience.com](mailto:info@ovationscience.com) or Phone 604.283.0903

[www.ovationscience.com](http://www.ovationscience.com)